IP Library › Granted Patent US 11,117,924
Granted Patent B2
US 11,117,924 · App. 15/742,424 · Granted Sep 14, 2021

Oxysterols and methods of use thereof

Inventors: Francesco G. Salituro (Marlborough, MA); Albert Jean Robichaud (Cambridge, MA); Gabriel Martinez Botella (Wayland, MA); Boyd L. Harrison (Princeton Junction, NJ)
Assignee: SAGE THERAPEUTICS, INC.
C07J9/00A61P3/00A61P23/00A61P25/20C07J17/00C07J7/002C07J9/005C07J13/005C07J13/007C07J31/006C07J41/0061
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,117,924
App. No.
15/742,424
Granted
Sep 14, 2021
Kind
B2
Abstract

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R 1 , R 2 , and R 3 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Claims (15)

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is substituted or unsubstituted C 1-6 alkyl;

R 2 is selected from the group consisting of cyclobutyl, cyclopentyl, and cyclohexyl;

R 5 is absent or hydrogen; and

represents a single or double bond, wherein when one is a double bond, the other is a single bond and R 5 is absent.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is substituted C 1-6 alkyl.

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is unsubstituted C 1-6 alkyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is methyl or ethyl.

5. The compound of claim 1 , wherein the compound of Formula (I) is a compound of Formula (I-A) or Formula (I-B):

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound of Formula (I) is selected from:

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. A method of inducing sedation or anesthesia comprising administering to a subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, or pharmaceutical composition thereof.

Assignments (3)
CHANGE OF NAME Recorded Mar 17, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075169/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2025
From: SALITURO, FRANCESCO G.; ROBICHAUD, ALBERT JEAN; BOTELLA, GABRIEL MARTINEZ
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071340/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2025
From: BOTELLA, GABRIEL MARTINEZ; HARRISON, BOYD L.; ROBICHAUD, ALBERT JEAN; SALITURO, FRANCESCO G.
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071510/0754 →
Continuity (3)
Provisional Application 62189068 · Jul 6, 2015
Provisional Application 62332931 · May 6, 2016
Related Publication 20180194797A1 · Jul 12, 2018
Cited By (2)
US 12,448,409 US 12,540,157